Ldl Cholesterol

Evinacumab, a novel fully human monoclonal antibody against angiopoietin-like 3, reduced LDL by more than 50% compared with placebo in patients with refractory hypercholesterolemia, researchers reported.

Management of lipids and residual cardiovascular risk has been a growing concern in endocrinology, and new data in this area are encouraging.

Timing of LDL lowering with evolocumab (Repatha, Amgen) shortly after ACS.

The number of adults with severe hypercholesterolemia prescribed general and high-intensity statins in a Kentucky health system falls below recommended guidelines, according to a study published in The American Journal of Cardiology.

The 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol does not flag most younger patients with premature MI as candidates for statin therapy before their event, researchers found.

Patients who were given evolocumab shortly after ACS had rapid and significant LDL reductions in 24 hours, researchers found in the EVACS trial.

Significant disparities persist regarding secondary prevention for CHD, particularly for treatment, risk factor control and medical therapy adherence, researchers found.

A machine learning algorithm to identify patients with familial hypercholesterolemia was successfully implemented in a large health care system, according to a presentation.

LDL reduction with alirocumab (Praluent, Sanofi/Regeneron) every 2 weeks vs. placebo in patients with homozygous familial hypercholesterolemia.

Management of lipids and residual CV risk has been a primary focus in cardiology for decades, and new data in this area are encouraging. Much emphasis has been placed on the use of therapies including PCSK9 inhibitors, statins and ezetimibe to achieve target LDL levels. But controlling LDL does not always control CVD risk, and because some patients are not able to achieve LDL and other targets on existing therapies, new options are needed.